---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021152"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:02:15.957106+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical reports Q4 revenue $62.2M (+25% YoY), FY2023 $187.1M (+32%); guides FY2024 $220-225M

## Summary
- Q4 2023 revenue $62.2M, up 25% YoY; full-year revenue $187.1M, up 32%, above guidance of $182-186M.
- Q4 net loss ($6.3M) ($0.10/share); full-year net loss ($49.5M) ($0.81/share); adjusted net loss same.
- Active surgeons reached 2,855 (+20% YoY); direct sales reps 227 (+35% YoY).
- FY2024 revenue guidance $220-225M (18-20% growth); expects ~50% improvement in Adjusted EBITDA.
- Launched SpeedPlate, Micro-Lapiplasty, Hammertoe Fixation; patent portfolio 57 granted US patents.

## SEC filing metadata
- accession: 0000950170-24-021152
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/0000950170-24-021152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/tmci-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021152
- JSON: https://secwatch.observer/filing/0000950170-24-021152.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021152.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).
  - Period: the quarter and year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 27, 2024, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/0000950170-24-021152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.